Eric Tran et al. had identified a CD4+ T cell epitope ERBB2IP-E805G derived from a metastatic cholangiocarcinoma patient; they found that mutation-reactive CD4+ Th1 cells could be used to mediate the regression of the tumor [40]. This evidence concerns the gene CD4 and cholangiocarcinoma.